Announcements Trials
Browse Landscape

Phase

Phase 3 13Phase 2 12Phase 1 7Phase 1/2 2Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoid Malignancies 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 4Cyclophosphamide 4pirtobrutinib 3fludarabine 2Chlorambucil 2venetoclax 1ofatumumab 1idelalisib 1ibrutinib 1fludarabine phosphate 1acalabrutinib 1Valganciclovir 1Thiotepa 1Sirolimus 1Radiotherapy 1Prednisone 1Pneumococcal Vaccines 1Pentostatin 1Filgrastim 1Everolimus 1Biopsy, Needle 1Bendamustine Hydrochloride 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Leukemia, Lymphocytic, Chronic, B-Cell × idelalisib × Clear all
NCT07218341 2026-05-22

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Eli Lilly and Company

Phase 4 Recruiting
150 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡